Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883593 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
A Early Phase 1 study of Tinea Pedis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT04883593 is a Early Phase 1 study of Tinea Pedis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 160 participants, below the 309-participant average among 9 other Tinea Pedis trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04883593, a Early Phase 1 study of Tinea Pedis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG TA103
Study Locations (1)
North Carolina
- Catawba Research, LLC - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2021-02-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04883593
The ClinicalTrials.gov registry entry for NCT04883593 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 309-participant average among 9 other Tinea Pedis trials with a reported enrollment target (48% lower). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Control is the first listed.
NCT04883593 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04883593 about?
NCT04883593 is a clinical study titled "A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.". To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
What is the current status of trial NCT04883593?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 160 participants. The study started on 2020-09-03. Estimated completion is 2021-02-20.
What conditions does trial NCT04883593 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT04883593?
The interventions under investigation include: Placebo Control (DRUG), TA103 (DRUG).
Who is sponsoring clinical trial NCT04883593?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883593 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.